Therefore, a series of drugs targeting the VHL-HIF2α-VEGFA axis in RCC were investigated and developed, like PT2399, VEGFA inhibitor, or sunitinib [9, 10]. The gene discussed is VEGFA; the disease is renal cell carcinoma.